Oklo Gets DOE Nod for Groves Test Reactor, But Commercial Hurdles Remain

What happened

Oklo received startup authorization from the U.S. Department of Energy for its Groves Isotope Test Reactor, clearing the way for fuel loading and first criticality. This is a positive technical milestone, but it's for a low-power test reactor, not the commercial Aurora powerhouse that drives the investment thesis. The DeepValue report notes that peer Antares already achieved criticality in June 2026, so Oklo still lags on the milestone that matters most for credibility. Despite this progress, Oklo still has no operating revenue, no binding power purchase agreements, and no definitive fuel supply commitments with disclosed terms. The stock's $7.6B market cap continues to rely on future commercial conversion rather than current proof.

Implication

For investors, the news is a modest positive that validates Oklo's ability to navigate DOE processes, but it does not change the underlying thesis. The company remains a pre-revenue developer with a strong balance sheet but no visible path to near-term revenue. The stock still trades at ~3x book value, implying a premium that relies on flawless execution across Idaho, Ohio, and fuel supply. Without a binding PPA or plant-specific fuel agreement within the next six months, the narrative risk remains significant. Key watchpoints are conversion of the Centrus LOI into a firm contract, further NRC licensing progress, and Ohio site development. The attractive entry remains $36, with a trim level at $58, and the WAIT rating is maintained.

Thesis delta

The Groves authorization is a procedural win but does not alter the investment thesis. The core milestones—binding customer contracts, committed fuel supply, and commercial licensing—remain unchanged. The call stays WAIT until hard commitments emerge.